{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:04Z","timestamp":1761519064046,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.breast.2013.03.012","type":"journal-article","created":{"date-parts":[[2013,4,30]],"date-time":"2013-04-30T23:53:05Z","timestamp":1367365985000},"page":"470-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"Matteo","family":"Clavarezza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Turazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Aitini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Saracchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Durando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Levaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Bighin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Restuccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Scalamogna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2013.03.012_bib1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","volume":"30","author":"Wolmark","year":"2001","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.breast.2013.03.012_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.breast.2013.03.012_bib4","doi-asserted-by":"crossref","first-page":"vi12","DOI":"10.1093\/annonc\/mdr371","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Aebi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/annonc\/mdm201","article-title":"Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006","volume":"18","author":"Kaufmann","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib6","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.2006.09.1777","article-title":"Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony- stimulating factor in operable breast cancer: results of ABCSG-14","volume":"25","author":"Steger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib7","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group","volume":"23","author":"von Minckwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.03.012_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jnci\/djn089","article-title":"Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.03.012_bib10","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2005.06.156","article-title":"Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study","volume":"23","author":"Evans","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib11","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2008.20.3133","article-title":"Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer","volume":"27","author":"Untch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib12","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.breast.2013.03.012_bib13","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.3816\/CBC.2002.s.015","article-title":"Aberdeen Breast Group. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial","volume":"3","author":"Heys","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2013.03.012_bib14","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl. 7","key":"10.1016\/j.breast.2013.03.012_bib15","article-title":"ABCSG-24: efficacy of anthracycline- and taxane-based neoadjuvant therapy \u00b1 capecitabine (C) in triple-negative early breast cancer (TNBC)","volume":"21","author":"Steger","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","article-title":"Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study","volume":"28","author":"von Minckwitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.522","article-title":"Neo-tAnGo: a neoadjuvant randomized phase III trial ofepirubicin\/cyclophosphamide and paclitaxel \u00b1 gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR)","volume":"27","author":"Earl","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa1111097","article-title":"Bevacizumab added to neoadjuvant chemotherapy for breast cancer","volume":"366","author":"Bear","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2013.03.012_bib19","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2013.03.012_bib20","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo- controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib22","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/jnci\/84.24.1875","article-title":"Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma","volume":"84","author":"Weidner","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2013.03.012_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.breast.2013.03.012_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3816\/CBC.2003.n.039","article-title":"The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer","volume":"4","author":"Linderholm","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2013.03.012_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clbc.2011.04.001","article-title":"Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2-locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group","volume":"11","author":"Rastogi","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2013.03.012_bib26","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1200\/JCO.2005.03.4645","article-title":"Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer","volume":"4","author":"Wedam","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.breast.2013.03.012_bib27","article-title":"Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer","volume":"69","author":"Makhoul","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.03.012_bib28","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ejso.2009.01.014","article-title":"Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2\/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study","volume":"35","author":"Greil","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"15s(Suppl.)","key":"10.1016\/j.breast.2013.03.012_bib29","article-title":"Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy","volume":"27","author":"Ryan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CAD.0b013e3283264719","article-title":"Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features","volume":"20","author":"Balduzzi","year":"2009","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.breast.2013.03.012_bib31","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl. 24","key":"10.1016\/j.breast.2013.03.012_bib32","first-page":"452s","article-title":"Meta-analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC)","volume":"70","author":"O'Shaughnessy","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2013.03.012_bib33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","article-title":"Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial","volume":"133","author":"Brufsky","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2013.03.012_bib34","article-title":"Primary results of Beatrice, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer","author":"Cameron","year":"2012","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.breast.2013.03.012_bib35","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/cncr.25872","article-title":"Impact of neoadjuvant chemotherapy on breast reconstruction","volume":"117","author":"Hu","year":"2011","journal-title":"Cancer"},{"issue":"29 (Suppl.)","key":"10.1016\/j.breast.2013.03.012_bib36","article-title":"Postoperative complications in neoadjuvant treatment including bevacizumab for HER2-positive inflammatory breast cancer (IBC): results from a phase II prospective trial","author":"Rouzier","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2013.03.012_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1245\/s10434-010-1366-8","article-title":"Does neoadjuvant bevacizumab increase surgical complications in breast surgery?","volume":"18","author":"Golshan","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"Suppl. 24","key":"10.1016\/j.breast.2013.03.012_bib38","article-title":"Surgical complications from the GeparQuinto trial of patients receiving preoperative bevacizumab","volume":"71","author":"Eidtmann","year":"2011","journal-title":"Cancer Res"},{"issue":"Suppl. 24","key":"10.1016\/j.breast.2013.03.012_bib39","article-title":"The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40","volume":"71","author":"Bear","year":"2011","journal-title":"Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977613000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:30:13Z","timestamp":1760776213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977613000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0960977613000805"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2013.03.012","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2013.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}